Literature DB >> 28035516

Circadian Rhythm of Methylated Septin 9, Cell-Free DNA Amount and Tumor Markers in Colorectal Cancer Patients.

Kinga Tóth1, Árpád V Patai2, Alexandra Kalmár2,3, Barbara Kinga Barták2, Zsófia Brigitta Nagy2, Orsolya Galamb3, Barnabás Wichmann3, Zsolt Tulassay2,3, Béla Molnár2,3.   

Abstract

To determine the level of cell-free DNA (cfDNA), Septin 9 (SEPT9) and tumor markers (CEA, AFP, CA19-9, TPA, CA72-4). Plasma samples were collected four times a day (06:00, 12:00, 18:00, 24:00) from 9 patients with CRC (5 stage I-II, 4 stage III-IV), from one with colorectal adenoma and from one healthy control. CfDNA was isolated, quantified and bisulfite-converted. CfDNA and methylated SEPT9 were determined by RT-PCR. Plasma levels of conventional tumor markers were also measured. The lowest cfDNA concentrations were observed at 24:00 and 18:00 in stage I-III patients. In stage IV samples low cfDNA level (mean 48.2 ng/ml) were observed at several time points (6:00, 12:00, 18:00). The highest cfDNA levels were measured at 6:00 and 12:00 in CRC I-III stages and at 24:00 in stage IV samples (78.65 ng/ml). Higher in-day differences were found in stage II (43-48%) than in stage I samples (22%). Interestingly, the highest SEPT9 methylation level was found at 24:00 in most CRC cases, in contrast to the cfDNA levels. At 24:00, all cancer and adenoma cases were positive for SEPT9 methylation. At other time points (6:00, 12:00, 18:00) only 77.7% of CRC samples showed SEPT9 positivity. Stage I samples were SEPT9 positive only at 24:00. CEA and CA19-9 levels displayed correlation with the amount of cfDNA in case of late stage cases. Daytime activity can influence SEPT9 positivity in cases with low concentration of cfDNA. Thus, it may improve screening sensitivity by collecting samples earlier in the morning.

Entities:  

Keywords:  Cell-free DNA; Circadian rhythm; Colorectal cancer; SEPT9; Tumor markers

Mesh:

Substances:

Year:  2016        PMID: 28035516     DOI: 10.1007/s12253-016-0174-2

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  44 in total

1.  About the possible origin and mechanism of circulating DNA apoptosis and active DNA release.

Authors:  M Stroun; J Lyautey; C Lederrey; A Olson-Sand; P Anker
Journal:  Clin Chim Acta       Date:  2001-11       Impact factor: 3.786

Review 2.  Prenatal diagnosis using cell-free nucleic acids in maternal body fluids: a decade of progress.

Authors:  Jill L Maron; Diana W Bianchi
Journal:  Am J Med Genet C Semin Med Genet       Date:  2007-02-15       Impact factor: 3.908

3.  Complete blood counts with differential: more accurate reference ranges based on circadian leukocyte trafficking.

Authors:  Stan Braude; Andrew Beck
Journal:  J Clin Pathol       Date:  2013-08-12       Impact factor: 3.411

4.  Circadian clock coordinates cancer cell cycle progression, thymidylate synthase, and 5-fluorouracil therapeutic index.

Authors:  Patricia A Wood; Jovelyn Du-Quiton; Shaojin You; William J M Hrushesky
Journal:  Mol Cancer Ther       Date:  2006-08       Impact factor: 6.261

5.  Regulation of apoptosis by the circadian clock through NF-kappaB signaling.

Authors:  Jin Hyup Lee; Aziz Sancar
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-20       Impact factor: 11.205

6.  Effects of sleep and circadian rhythm on human circulating immune cells.

Authors:  J Born; T Lange; K Hansen; M Mölle; H L Fehm
Journal:  J Immunol       Date:  1997-05-01       Impact factor: 5.422

7.  Cancer-associated alteration of circadian rhythms in carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in humans.

Authors:  C Focan; D Focan-Henrard; J Collette; M Mechkouri; F Levi; W Hrushesky; Y Touitou; P Franchimont
Journal:  Anticancer Res       Date:  1986 Sep-Oct       Impact factor: 2.480

8.  Exercise is a potent stimulus for enhancing circulating DNase activity.

Authors:  Martina Velders; Gunnar Treff; Katja Machus; Edit Bosnyák; Jürgen Steinacker; Uwe Schumann
Journal:  Clin Biochem       Date:  2013-12-27       Impact factor: 3.281

9.  Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer.

Authors:  Jorja D Warren; Wei Xiong; Ashley M Bunker; Cecily P Vaughn; Larissa V Furtado; William L Roberts; John C Fang; Wade S Samowitz; Karen A Heichman
Journal:  BMC Med       Date:  2011-12-14       Impact factor: 8.775

10.  Assessment of the biological variation of plasma tissue inhibitor of metalloproteinases-1.

Authors:  C B Frederiksen; A F Lomholt; T Lottenburger; G J Davis; B L Dowell; M A Blankenstein; I J Christensen; N Brunner; H J Nielsen
Journal:  Int J Biol Markers       Date:  2008 Jan-Mar       Impact factor: 3.248

View more
  9 in total

Review 1.  Critical issues in the clinical application of liquid biopsy in non-small cell lung cancer.

Authors:  Mariangela Manicone; Cristina Poggiana; Antonella Facchinetti; Rita Zamarchi
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

Review 2.  The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review.

Authors:  Ian A Cree; Lesley Uttley; Helen Buckley Woods; Hugh Kikuchi; Anne Reiman; Susan Harnan; Becky L Whiteman; Sian Taylor Philips; Michael Messenger; Angela Cox; Dawn Teare; Orla Sheils; Jacqui Shaw
Journal:  BMC Cancer       Date:  2017-10-23       Impact factor: 4.430

3.  Quantifying circulating cell-free DNA in humans.

Authors:  Romain Meddeb; Zahra Al Amir Dache; Simon Thezenas; Amaëlle Otandault; Rita Tanos; Brice Pastor; Cynthia Sanchez; Joelle Azzi; Geoffroy Tousch; Simon Azan; Caroline Mollevi; Antoine Adenis; Safia El Messaoudi; Philippe Blache; Alain R Thierry
Journal:  Sci Rep       Date:  2019-03-26       Impact factor: 4.379

4.  Age-stratified reference intervals unlock the clinical potential of circulating cell-free DNA as a biomarker of poor outcome for healthy individuals and patients with colorectal cancer.

Authors:  Mai-Britt Worm Ørntoft; Sarah Østrup Jensen; Nadia Øgaard; Tenna Vesterman Henriksen; Linnea Ferm; Ib Jarle Christensen; Thomas Reinert; Ole Halfdan Larsen; Hans Jørgen Nielsen; Claus Lindbjerg Andersen
Journal:  Int J Cancer       Date:  2020-12-21       Impact factor: 7.396

Review 5.  The influence of biological and lifestyle factors on circulating cell-free DNA in blood plasma.

Authors:  Nicole Laurencia Yuwono; Kristina Warton; Caroline Elizabeth Ford
Journal:  Elife       Date:  2021-11-09       Impact factor: 8.140

6.  Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study.

Authors:  Julia Bergheim; Alexander Semaan; Heidrun Gevensleben; Susanne Groening; Andreas Knoblich; Jörn Dietrich; Julia Weber; Jörg C Kalff; Friedrich Bootz; Glen Kristiansen; Dimo Dietrich
Journal:  Br J Cancer       Date:  2018-04-03       Impact factor: 7.640

Review 7.  The Use of Circulating Tumor DNA for Prognosis of Gastrointestinal Cancers.

Authors:  Hariti Saluja; Christos S Karapetis; Susanne K Pedersen; Graeme P Young; Erin L Symonds
Journal:  Front Oncol       Date:  2018-07-24       Impact factor: 6.244

8.  Circadian rhythms in the pathogenesis of gastrointestinal diseases.

Authors:  Pilar Codoñer-Franch; Marie Gombert
Journal:  World J Gastroenterol       Date:  2018-10-14       Impact factor: 5.742

Review 9.  How to Obtain a High Quality ctDNA in Lymphoma Patients: Preanalytical Tips and Tricks.

Authors:  Estelle Bourbon; Vincent Alcazer; Estelle Cheli; Sarah Huet; Pierre Sujobert
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.